330 Complete surgical cytoreduction remains pivotal in achieving better survival outcomes in patients with advanced ovarian cancer with a BRCA1/2 germline mutation in the pre-parp inhibitor ERA
330 Complete surgical cytoreduction remains pivotal in achieving better survival outcomes in patients with advanced ovarian cancer with a BRCA1/2 germline mutation in the pre-parp inhibitor ERA